PMID- 38102213
OWN - NLM
STAT- MEDLINE
DCOM- 20240209
LR  - 20240304
IS  - 1476-5365 (Electronic)
IS  - 0268-3369 (Linking)
VI  - 59
IP  - 2
DP  - 2024 Feb
TI  - Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR 
      T-cell therapy.
PG  - 162-170
LID - 10.1038/s41409-023-02176-0 [doi]
AB  - In recent years, chimeric antigen receptor T-cell therapy (CAR T) has 
      revolutionized the treatment landscape for large B cell lymphoma (LBCL), 
      demonstrating remarkable efficacy and ushering a new era of therapeutic 
      possibilities. However, a subset of patients may not achieve the desired response 
      with CAR T. This review examines strategies aimed at optimizing outcomes for 
      patients who relapse or progress after CAR T. Available data on utilization of 
      CD19-directed monoclonal antibodies and antibody drug conjugates have shown 
      limited efficacy in this setting. Moreover, bispecific antibodies have also 
      emerged as an alternative therapy in relapsed and or refractory LBCL, but 
      long-term follow up treated cases post-CAR T failure are lacking. Several 
      observational studies have shown efficacy of allogeneic hematopoietic cell 
      transplantation, but attainment of a complete remission prior to allografting is 
      a prerequisite to achieve durable remissions. As we navigate the intricate 
      landscape of treatment of post CAR T failure, it becomes evident that this 
      represents a therapeutic challenge which necessitates a multifaceted approach.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Limited.
FAU - El Warrak, Samantha
AU  - El Warrak S
AD  - Department of Internal Medicine, University of Connecticut, Farmington, CT, USA.
FAU - Kharfan-Dabaja, Mohamed A
AU  - Kharfan-Dabaja MA
AUID- ORCID: 0000-0001-7394-5185
AD  - Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular 
      Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
FAU - Iqbal, Madiha
AU  - Iqbal M
AUID- ORCID: 0000-0001-6752-5440
AD  - Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular 
      Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
FAU - Hamadani, Mehdi
AU  - Hamadani M
AUID- ORCID: 0000-0001-5372-510X
AD  - Blood and Marrow Transplantation Program, Medical College of Wisconsin, 
      Milwaukee, WI, USA.
FAU - Chavez, Julio
AU  - Chavez J
AUID- ORCID: 0000-0002-2045-6238
AD  - Department of Blood and Marrow Transplantation and Cellular Immunotherapy, 
      Moffitt Cancer Center, Tampa, FL, USA.
FAU - Mohty, Razan
AU  - Mohty R
AUID- ORCID: 0000-0002-0189-8233
AD  - Division of Hematology and Oncology, Department of Medicine, University of 
      Alabama at Birmingham, Birmingham, AL, USA. rmohty@uab.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231216
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive/adverse effects
MH  - *Receptors, Chimeric Antigen
MH  - Neoplasm Recurrence, Local
MH  - *Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy
MH  - Antigens, CD19
EDAT- 2023/12/16 11:43
MHDA- 2024/02/09 06:43
CRDT- 2023/12/15 23:31
PHST- 2023/10/21 00:00 [received]
PHST- 2023/12/01 00:00 [accepted]
PHST- 2023/11/29 00:00 [revised]
PHST- 2024/02/09 06:43 [medline]
PHST- 2023/12/16 11:43 [pubmed]
PHST- 2023/12/15 23:31 [entrez]
AID - 10.1038/s41409-023-02176-0 [pii]
AID - 10.1038/s41409-023-02176-0 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2024 Feb;59(2):162-170. doi: 10.1038/s41409-023-02176-0. 
      Epub 2023 Dec 16.